Center for Improving Patient and Population Health, University of Michigan, Ann Arbor, Michigan.
Cancer Control and Population Sciences Program, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):287-292. doi: 10.1158/1055-9965.EPI-21-0835. Epub 2021 Nov 4.
The US Health Retirement Study (HRS) is an ongoing population-representative cohort of US adults ages >50 with rich data on health during aging. Self-reported cancer diagnoses have been collected since 1998, but they have not been validated. We compared self-reported cancer diagnoses in HRS interviews against diagnostic claims from linked Medicare records.
Using HRS-Medicare linked data, we examined the validity of first incident cancer diagnoses self-reported in biennial interviews from 2000 to 2016 against ICD-9 and ICD-10 diagnostic claim records as the gold standard. Data were from 8,242 HRS participants ages ≥65 with 90% continuous enrollment in fee-for-service Medicare. We calculated the sensitivity, specificity, and κ for first incident invasive cancer diagnoses (all cancers combined, and each of bladder, breast, colorectal/anal, uterine, kidney, lung, and prostate cancers) cumulatively over the follow-up and at each biennial study interview.
Overall, self-reports of first incident cancer diagnoses from 2000 to 2016 had 73.2% sensitivity and 96.2% specificity against Medicare claims (κ = 0.73). For specific cancer types, sensitivities ranged from 44.7% (kidney) to 75.0% (breast), and specificities ranged from 99.2% (prostate) and 99.9% (bladder, uterine, and kidney). Results were similar in sensitivity analyses restricted to individuals with 100% continuous fee-for-service Medicare enrollment and when restricted to individuals with at least 24 months of Medicare enrollment.
Self-reported cancer diagnoses in the HRS have reasonable validity for use in population-based research that is maximized with linkage to Medicare.
These findings inform the use of the HRS for population-based cancer and aging research.
美国健康退休研究(HRS)是一项针对 50 岁以上美国成年人的正在进行的代表性队列研究,该研究中有丰富的老龄化过程中健康数据。自 1998 年以来,一直在收集自我报告的癌症诊断信息,但这些信息未经证实。我们将 HRS 访谈中的自我报告癌症诊断与从链接的医疗保险记录中获取的诊断索赔进行了比较。
使用 HRS 和医疗保险的链接数据,我们检查了 2000 年至 2016 年期间,在 HRS 访谈中每两年报告一次的首次癌症诊断的准确性,将 ICD-9 和 ICD-10 诊断索赔记录作为金标准。研究数据来自 8242 名年龄在 65 岁及以上的 HRS 参与者,他们 90%连续参加了医疗保险的付费服务。我们计算了在随访期间和每次两年一次的研究访谈中,首次发生的侵袭性癌症诊断(所有癌症合并、膀胱癌、乳腺癌、结直肠癌/肛门癌、子宫癌、肾癌、肺癌和前列腺癌)的敏感性、特异性和κ。
总体而言,2000 年至 2016 年自我报告的首次癌症诊断的敏感性为 73.2%,特异性为 96.2%,与医疗保险索赔相符(κ=0.73)。对于特定的癌症类型,敏感性范围从 44.7%(肾脏)到 75.0%(乳房),特异性范围从 99.2%(前列腺)到 99.9%(膀胱、子宫和肾脏)。在限制具有 100%连续医疗保险付费服务注册的个体和限制至少有 24 个月医疗保险注册的个体的敏感性分析中,结果相似。
HRS 中的自我报告癌症诊断具有合理的有效性,可用于基于人群的研究,通过与医疗保险的链接可最大限度地提高其有效性。
这些发现为 HRS 在基于人群的癌症和老龄化研究中的应用提供了信息。